Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis
Background and purpose Peripheral inflammation is probably involved in the pathogenesis of progressive supranuclear palsy (PSP) and it may be a common feature with Parkinson's disease (PD). The peripheral immune profile in PSP remains unclear, as well as whether the inflammatory pathways differ...
| Autores: | , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/387164 |
| Acceso en línea: | http://hdl.handle.net/10261/387164 https://api.elsevier.com/content/abstract/scopus_id/85201538105 |
| Access Level: | acceso abierto |
| Palabra clave: | Inflammation Neutrophil Neutrophil‐to‐lymphocyte ratio Progressive supranuclear palsy |
| id |
ES_108b76ca8d2b8960322dc6bdf810b178 |
|---|---|
| oai_identifier_str |
oai:digital.csic.es:10261/387164 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis |
| title |
Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis |
| spellingShingle |
Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis Muñoz-Delgado, Laura Inflammation Neutrophil Neutrophil‐to‐lymphocyte ratio Progressive supranuclear palsy |
| title_short |
Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis |
| title_full |
Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis |
| title_fullStr |
Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis |
| title_full_unstemmed |
Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis |
| title_sort |
Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysis |
| dc.creator.none.fl_str_mv |
Muñoz-Delgado, Laura Luque-Ambrosiani, Antonio Benítez Zamora, Belén Macías García, Daniel Jesús Maestre, Silvia Adarmes-Gómez, Astrid Ojeda-Lepe, Elena Carrillo, Fátima Mir, Pablo |
| author |
Muñoz-Delgado, Laura |
| author_facet |
Muñoz-Delgado, Laura Luque-Ambrosiani, Antonio Benítez Zamora, Belén Macías García, Daniel Jesús Maestre, Silvia Adarmes-Gómez, Astrid Ojeda-Lepe, Elena Carrillo, Fátima Mir, Pablo |
| author_role |
author |
| author2 |
Luque-Ambrosiani, Antonio Benítez Zamora, Belén Macías García, Daniel Jesús Maestre, Silvia Adarmes-Gómez, Astrid Ojeda-Lepe, Elena Carrillo, Fátima Mir, Pablo |
| author2_role |
author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Junta de Andalucía Agencia Estatal de Investigación (España) Ministerio de Ciencia, Innovación y Universidades (España) Instituto de Salud Carlos III European Commission Muñoz-Delgado, Laura [0000-0002-8818-1824] Macías García, Daniel [0000-0002-4822-1529] Mir, Pablo [0000-0003-1656-302X] Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72] |
| dc.subject.none.fl_str_mv |
Inflammation Neutrophil Neutrophil‐to‐lymphocyte ratio Progressive supranuclear palsy |
| topic |
Inflammation Neutrophil Neutrophil‐to‐lymphocyte ratio Progressive supranuclear palsy |
| description |
Background and purpose Peripheral inflammation is probably involved in the pathogenesis of progressive supranuclear palsy (PSP) and it may be a common feature with Parkinson's disease (PD). The peripheral immune profile in PSP remains unclear, as well as whether the inflammatory pathways differ from those in PD. The neutrophil-to-lymphocyte ratio (NLR) has been proven to be a well-established biomarker of systemic inflammation. This study aimed to evaluate the peripheral immune profile in PSP compared with PD. Methods A cross-sectional study was conducted including patients with PSP and PD and healthy controls (HCs). Leukocyte subpopulations and the NLR were measured in peripheral blood. Multivariate linear regression and post hoc tests were applied. Electronic databases were searched in November 2023 to perform meta-analyses to clarify the peripheral immune profile in PSP. Results Our cohort included 121 patients with PSP, 127 patients with PD and 266 HCs. The NLR was higher in PSP and PD compared with HCs. PSP had a higher neutrophil count compared with HCs. Whilst a lower lymphocyte count was found in PD compared with HCs, the lymphocyte count did not differ between PSP and HCs. The meta-analyses supported this immune profile. Conclusions PSP and PD show an increased peripheral inflammation and a higher NLR compared with HCs. Different pathogenic inflammatory mechanisms are probably involved in PSP and PD, since in PSP this altered peripheral immune profile is mainly driven by neutrophils. Understanding the neutrophils' role in PSP may allow for the development of targeted therapies. |
| publishDate |
2024 |
| dc.date.none.fl_str_mv |
2024 2025 2025 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 Publisher's version info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10261/387164 https://api.elsevier.com/content/abstract/scopus_id/85201538105 |
| url |
http://hdl.handle.net/10261/387164 https://api.elsevier.com/content/abstract/scopus_id/85201538105 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
#PLACEHOLDER_PARENT_METADATA_VALUE# info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTC2019-007150-1 https://doi.org/10.1111/ene.16451 Sí |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
John Wiley & Sons |
| publisher.none.fl_str_mv |
John Wiley & Sons |
| dc.source.none.fl_str_mv |
reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC instname:Consejo Superior de Investigaciones Científicas (CSIC) |
| instname_str |
Consejo Superior de Investigaciones Científicas (CSIC) |
| reponame_str |
DIGITAL.CSIC. Repositorio Institucional del CSIC |
| collection |
DIGITAL.CSIC. Repositorio Institucional del CSIC |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869403516013903872 |
| spelling |
Peripheral immune profile and neutrophil-to-lymphocyte ratio in progressive supranuclear palsy: Case-control study and meta-analysisMuñoz-Delgado, LauraLuque-Ambrosiani, AntonioBenítez Zamora, BelénMacías García, DanielJesús Maestre, SilviaAdarmes-Gómez, AstridOjeda-Lepe, ElenaCarrillo, FátimaMir, PabloInflammationNeutrophilNeutrophil‐to‐lymphocyte ratioProgressive supranuclear palsyBackground and purpose Peripheral inflammation is probably involved in the pathogenesis of progressive supranuclear palsy (PSP) and it may be a common feature with Parkinson's disease (PD). The peripheral immune profile in PSP remains unclear, as well as whether the inflammatory pathways differ from those in PD. The neutrophil-to-lymphocyte ratio (NLR) has been proven to be a well-established biomarker of systemic inflammation. This study aimed to evaluate the peripheral immune profile in PSP compared with PD. Methods A cross-sectional study was conducted including patients with PSP and PD and healthy controls (HCs). Leukocyte subpopulations and the NLR were measured in peripheral blood. Multivariate linear regression and post hoc tests were applied. Electronic databases were searched in November 2023 to perform meta-analyses to clarify the peripheral immune profile in PSP. Results Our cohort included 121 patients with PSP, 127 patients with PD and 266 HCs. The NLR was higher in PSP and PD compared with HCs. PSP had a higher neutrophil count compared with HCs. Whilst a lower lymphocyte count was found in PD compared with HCs, the lymphocyte count did not differ between PSP and HCs. The meta-analyses supported this immune profile. Conclusions PSP and PD show an increased peripheral inflammation and a higher NLR compared with HCs. Different pathogenic inflammatory mechanisms are probably involved in PSP and PD, since in PSP this altered peripheral immune profile is mainly driven by neutrophils. Understanding the neutrophils' role in PSP may allow for the development of targeted therapies.This work was supported by the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022), the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704, PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018, PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896). Several authors of this publication are members of the European Reference Network for Rare Neurological Diseases—Project ID No. 739510 and L.M.D. and P.M. are members of the COST Action IMMUPARKNET (CA21117). L. Muñoz-Delgado was supported by the ‘Río Hortega’ programme (CM21/00051) from the Instituto de Salud Carlos III, and has received support for attending meetings and/or travel or honorarium for lecturing from Abbvie, Merz and Italfarmaco. A. Luque-Ambrosiani and B. Benítez-Zamora report no disclosures. D. Macías-Garcia was supported by the ‘Juan Rodés’ programme (JR22/00073) from the Instituto de Salud Carlos III, and has received support for attending meetings and/or travel or honorarium for lecturing from Palex, Abbvie and Italfarmaco. S. Jesús has received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Abbvie, Bial, Italfarmaco, Merz and Zambon. AD Adarmes-Gómez has received support for attending meetings and/or travel or honorarium for lecturing from Abbvie, Bial, Italfarmaco, Merz, UCB and Zambon. F. Carrillo has received support for attending meetings and/or travel or honorarium for lecturing from Abbvie and Medtronic. E. Ojeda-Lepe was supported by the ‘Río Hortega’ programme (CM23/00288) from the Instituto de Salud Carlos III (ISCIII-FEDER), and has received support for attending meetings and/or travel or honorarium for lecturing from Abbvie, Bial, Esteve, Merz and Zambon. P. Mir has received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, Abbvie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon.Peer reviewedJohn Wiley & SonsJunta de AndalucíaAgencia Estatal de Investigación (España)Ministerio de Ciencia, Innovación y Universidades (España)Instituto de Salud Carlos IIIEuropean CommissionMuñoz-Delgado, Laura [0000-0002-8818-1824]Macías García, Daniel [0000-0002-4822-1529]Mir, Pablo [0000-0003-1656-302X]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202520252024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/387164https://api.elsevier.com/content/abstract/scopus_id/85201538105reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTC2019-007150-1https://doi.org/10.1111/ene.16451Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3871642026-05-22T06:33:51Z |
| score |
15.811543 |